Collaborators: Jerome Olagne and Sophie Caillard have equally contributed to this work. Marcellin L: Pathology Department, Parissiadis A: Etablissement Français du sang, Strasbourg, France. Thierry A, Goujon JM, Jollet I: Poitiers University Hospital, France. Ducloux D, Félix S, Chabot J: Besancon University Hospital, France. Essig M, Paraf F: Limoges University Hospital, France. Frimat L, Champigneulle J, Perrier P: Nancy University Hospital, France. Etienne I, François A: Rouen University Hospital, France. Legris T, Moal V, Daniel L: Marseille University Hospital, France. Toupance O, Diebold D, Tabarry T: Reims University Hospital, France. Moal MC, Doucet L: Brest University Hospital, France. Heng AE, Kemeny JL, Quainon F: Clermont-Ferrand University Hospital, France. Rivalan J, Rioux-Leclerc N: Rennes University Hospital, France. Rondeau E, Callard P: Tenon Hospital, Paris, France.
Post-transplant Lymphoproliferative Disorders: Determination of Donor/Recipient Origin in a Large Cohort of Kidney Recipients
Article first published online: 12 MAY 2011
©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 11, Issue 6, pages 1260–1269, June 2011
How to Cite
Olagne, J., Caillard, S., Gaub, M. P., Chenard, M. P. and Moulin, B. (2011), Post-transplant Lymphoproliferative Disorders: Determination of Donor/Recipient Origin in a Large Cohort of Kidney Recipients. American Journal of Transplantation, 11: 1260–1269. doi: 10.1111/j.1600-6143.2011.03544.x
- Issue published online: 6 JUN 2011
- Article first published online: 12 MAY 2011
- Received 27 October 2010, revised 06 march 2011 and accepted for publication 06 march 2011
- kidney transplantation;
- post-transplant lymphoproliferative disorders;
- tumoral cell origin
Although in previous studies most post-transplant lymphoproliferative disorders (PTLD) were reported to derive from recipient cells, some cases derived from donor lymphocytes have been reported. To provide a better description of the features and outcome of PTLD according to the origin of the lymphoma, we performed histologic and molecular studies of PTLD in kidney recipients. Forty-three specimens were analyzed by histochemistry, fluorescent hybridization of the Y chromosome and analysis of multiple short tandem repeat microsatellite loci. Sixteen tumors were shown to be of donor origin and 27 of recipient origin. Time to PTLD was shorter in donor-derived PTLDs (20±27 vs. 69±67 months, p = 0.013). Ten-year patient survival was similar among patients with recipient- and donor-derived PTLD, but when PTLD-related mortality was analyzed, there was a trend to better survival in patients with donor lymphomas. Among the 21 PTLDs localized in the allograft, 14 lymphomas were of donor origin and seven of recipient origin. No difference was found between the two groups. Our analysis of the origin of PTLDs in the largest cohort studied to date with a description of the clinical and histological characteristics of donor and recipient PTLDs should lead to a better understanding of lymphomagenesis.